JP2019534861A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534861A5 JP2019534861A5 JP2019514780A JP2019514780A JP2019534861A5 JP 2019534861 A5 JP2019534861 A5 JP 2019534861A5 JP 2019514780 A JP2019514780 A JP 2019514780A JP 2019514780 A JP2019514780 A JP 2019514780A JP 2019534861 A5 JP2019534861 A5 JP 2019534861A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 61
- 150000003839 salts Chemical class 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- -1 methoxypropyl Chemical group 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 229940124597 therapeutic agent Drugs 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 10
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 7
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 6
- 208000014644 Brain disease Diseases 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical class [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 208000019423 liver disease Diseases 0.000 claims description 4
- QDKWLJJOYIFEBS-UHFFFAOYSA-N 1-fluoro-4-$l^{1}-oxidanylbenzene Chemical group [O]C1=CC=C(F)C=C1 QDKWLJJOYIFEBS-UHFFFAOYSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000005107 Premature Birth Diseases 0.000 claims description 3
- 208000017442 Retinal disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000006712 (C1-C4) deuteroalkyl group Chemical group 0.000 claims description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 102000013918 Apolipoproteins E Human genes 0.000 claims description 2
- 108010025628 Apolipoproteins E Proteins 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000004051 Chronic Traumatic Encephalopathy Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000004575 Infectious Arthritis Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 206010036590 Premature baby Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010044688 Trisomy 21 Diseases 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 125000006242 amine protecting group Chemical group 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 230000008499 blood brain barrier function Effects 0.000 claims description 2
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 2
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 201000006517 essential tremor Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 claims description 2
- 230000002025 microglial effect Effects 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 238000010791 quenching Methods 0.000 claims description 2
- 230000000171 quenching effect Effects 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 201000001223 septic arthritis Diseases 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940122601 Esterase inhibitor Drugs 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
- 229960001231 choline Drugs 0.000 claims 1
- 239000002329 esterase inhibitor Substances 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 0 CC(NC(*)(C*C(*)(CN(*)*)C=C)C(*)=O)=O Chemical compound CC(NC(*)(C*C(*)(CN(*)*)C=C)C(*)=O)=O 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 150000002366 halogen compounds Chemical class 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- DOHXJAQSKHNDLH-INIZCTEOSA-N NCCCC[C@@H](C(COc(c(F)ccc1)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(c(F)ccc1)c1F)=O)NC(C1CCCC1)=O DOHXJAQSKHNDLH-INIZCTEOSA-N 0.000 description 1
- OLIMBXKACVCIMM-HNNXBMFYSA-N NCCCC[C@@H](C(COc(c(F)ccc1F)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(c(F)ccc1F)c1F)=O)NC(C1CCCC1)=O OLIMBXKACVCIMM-HNNXBMFYSA-N 0.000 description 1
- NBIIDGAHKKJKHI-HNNXBMFYSA-N NCCCC[C@@H](C(COc(cc(cc1F)F)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(cc(cc1F)F)c1F)=O)NC(C1CCCC1)=O NBIIDGAHKKJKHI-HNNXBMFYSA-N 0.000 description 1
- CJMLKFUQJAPXLR-INIZCTEOSA-N NCCCC[C@@H](C(COc(cccc1)c1F)=O)NC(C1CCCC1)=O Chemical compound NCCCC[C@@H](C(COc(cccc1)c1F)=O)NC(C1CCCC1)=O CJMLKFUQJAPXLR-INIZCTEOSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395938P | 2016-09-16 | 2016-09-16 | |
| US62/395,938 | 2016-09-16 | ||
| US201762459456P | 2017-02-15 | 2017-02-15 | |
| US62/459,456 | 2017-02-15 | ||
| PCT/US2017/051912 WO2018053353A1 (en) | 2016-09-16 | 2017-09-15 | Ketone inhibitors of lysine gingipain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019534861A JP2019534861A (ja) | 2019-12-05 |
| JP2019534861A5 true JP2019534861A5 (https=) | 2020-11-05 |
| JP7113815B2 JP7113815B2 (ja) | 2022-08-05 |
Family
ID=61618978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514780A Active JP7113815B2 (ja) | 2016-09-16 | 2017-09-15 | リシンジンジパインのケトン阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US10730826B2 (https=) |
| EP (2) | EP4480541A3 (https=) |
| JP (1) | JP7113815B2 (https=) |
| KR (1) | KR102780603B1 (https=) |
| CN (1) | CN109983012B (https=) |
| AU (2) | AU2017326466B2 (https=) |
| CA (1) | CA3036862A1 (https=) |
| CL (1) | CL2019000687A1 (https=) |
| CO (1) | CO2019002950A2 (https=) |
| DK (1) | DK3512846T3 (https=) |
| ES (1) | ES2992410T3 (https=) |
| IL (1) | IL265389A (https=) |
| MX (1) | MX2019003087A (https=) |
| PE (1) | PE20190473A1 (https=) |
| PH (1) | PH12019500570A1 (https=) |
| RU (1) | RU2019111188A (https=) |
| TW (1) | TWI787202B (https=) |
| WO (1) | WO2018053353A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12318377B2 (en) | 2013-12-20 | 2025-06-03 | Seed Health, Inc. | Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being |
| ES2992410T3 (es) | 2016-09-16 | 2024-12-12 | Lighthouse Pharmaceuticals Inc | Inhibidores cetónicos de la lisina gingipaína |
| CN110944637A (zh) | 2017-05-10 | 2020-03-31 | 库特克希米公司 | 氨基吡啶化合物及其制备方法和使用方法 |
| CN113195641B (zh) * | 2018-12-20 | 2024-09-03 | 武田药品工业株式会社 | 用作半胱氨酸蛋白酶的探针的氧化锍叶立德衍生物 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| CA1341029C (en) | 1985-02-04 | 2000-06-20 | Michael Kolb | Peptidase inhibitors |
| US5055451A (en) * | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| JPH01163162A (ja) | 1987-12-18 | 1989-06-27 | Showa Denko Kk | アミノ酸誘導体および酵素阻害剤 |
| US5723218A (en) | 1990-04-16 | 1998-03-03 | Molecular Probes, Inc. | Dipyrrometheneboron difluoride labeled flourescent microparticles |
| US5326692B1 (en) | 1992-05-13 | 1996-04-30 | Molecular Probes Inc | Fluorescent microparticles with controllable enhanced stokes shift |
| US5451410A (en) | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
| AU2299592A (en) | 1991-07-02 | 1993-02-11 | Children's Medical Center Corporation | Treatment of periodontal disease with protease inhibitors |
| US5576424A (en) | 1991-08-23 | 1996-11-19 | Molecular Probes, Inc. | Haloalkyl derivatives of reporter molecules used to analyze metabolic activity in cells |
| SE9102462D0 (sv) | 1991-08-28 | 1991-08-28 | Astra Ab | New isosteric peptides |
| CA2119126C (en) | 1991-09-16 | 1996-09-03 | Molecular Probes, Inc. | Dimers of unsymmetrical cyanine dyes |
| US5374623A (en) | 1992-08-20 | 1994-12-20 | Prototek, Inc. | Cysteine protease inhibitors effective for in vivo use |
| US5658751A (en) | 1993-04-13 | 1997-08-19 | Molecular Probes, Inc. | Substituted unsymmetrical cyanine dyes with selected permeability |
| WO1996019483A1 (en) | 1994-12-22 | 1996-06-27 | Biochem Pharma Inc. | Low molecular weight bicyclic thrombin inhibitors |
| US5656449A (en) | 1995-03-06 | 1997-08-12 | Molecular Probes, Inc. | Neutral unsymmetrical cyanine dyes |
| EP0815123B1 (en) | 1995-03-24 | 2001-10-04 | Molecumetics, Ltd. | Beta-sheet mimetics and use thereof as protease inhibitors |
| WO1996030396A1 (en) | 1995-03-24 | 1996-10-03 | Molecumetics Ltd. | β-SHEET MIMETICS AND USE THEREOF AS PROTEASE INHIBITORS |
| GB9510264D0 (en) | 1995-05-22 | 1995-07-19 | Iaf Biochem Int | Low molecular weight bicyclic-urea type thrombin inhibitors |
| US6596522B2 (en) | 1997-05-08 | 2003-07-22 | The Regents Of The University Of California | Detection of transmembrane potentials by optical methods |
| US5827866A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US5798276A (en) | 1995-06-07 | 1998-08-25 | Molecular Probes, Inc. | Reactive derivatives of sulforhodamine 101 with enhanced hydrolytic stability |
| US5827860A (en) | 1995-06-07 | 1998-10-27 | Ortho Pharmaceutical Corporation | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| US5523308A (en) | 1995-06-07 | 1996-06-04 | Costanzo; Michael J. | Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| IL119466A (en) | 1995-11-03 | 2001-08-26 | Akzo Nobel Nv | Thrombin inhibitors, their preparation and pharmaceutical compositions containing them |
| US6004536A (en) | 1995-11-14 | 1999-12-21 | Molecular Probes, Inc. | Lipophilic cyanine dyes with enchanced aqueous solubilty |
| US6162931A (en) | 1996-04-12 | 2000-12-19 | Molecular Probes, Inc. | Fluorinated xanthene derivatives |
| US6005113A (en) | 1996-05-15 | 1999-12-21 | Molecular Probes, Inc. | Long wavelength dyes for infrared tracing |
| US5846737A (en) | 1996-07-26 | 1998-12-08 | Molecular Probes, Inc. | Conjugates of sulforhodamine fluorophores with enhanced fluorescence |
| CA2262900A1 (en) | 1996-08-05 | 1998-02-12 | Molecumetics Ltd. | Use of beta-sheet mimetics as protease and kinase inhibitors and as inhibitors of transcription factors |
| AU4172397A (en) | 1996-09-06 | 1998-03-26 | Biochem Pharma Inc. | Lactam inhibitors of thrombin |
| US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
| US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
| WO1999026925A1 (en) | 1997-11-26 | 1999-06-03 | Yoshitomi Pharmaceutical Industries, Ltd. | Tryptase inhibitors comprising heterocyclic amide compounds |
| AU748887B2 (en) | 1998-02-12 | 2002-06-13 | Myriad Genetics, Inc. | Beta-sheet mimetics and methods relating to the use thereof |
| US6323219B1 (en) | 1998-04-02 | 2001-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Methods for treating immunomediated inflammatory disorders |
| US7053056B2 (en) | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| JP2002528723A (ja) | 1998-10-27 | 2002-09-03 | モレキュラー・プロウブズ・インコーポレーテッド | 遷移金属錯体を含有する発光タンパク質染色剤 |
| TR200102766T2 (tr) | 1999-01-27 | 2001-12-21 | Ortho-Mcneil Pharmaceutical, Inc. | Triptaz inhibitörü olarak kullanılan peptidil heterosiklik ketonlar |
| HK1039110A1 (zh) | 1999-03-15 | 2002-04-12 | Axys Pharmaceuticals, Inc. | 以新颖的合成物及组分作为蛋白酶抑制剂 |
| WO2000064988A1 (en) | 1999-04-23 | 2000-11-02 | Molecular Probes, Inc. | Xanthene dyes and their application as luminescence quenching compounds |
| US6790989B2 (en) | 2000-01-13 | 2004-09-14 | Idun Pharmaceuticals, Inc. | Inhibitors of the ICE/ced-3 family of cysteine proteases |
| AU2001243441B2 (en) * | 2000-03-21 | 2004-11-25 | Smithkline Beecham Corporation | Protease inhibitors |
| EP1311487B1 (en) | 2000-08-04 | 2008-11-26 | Molecular Probes, Inc. | Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings |
| US6579718B1 (en) | 2000-08-04 | 2003-06-17 | Molecular Probes, Inc. | Carbazolylvinyl dye protein stains |
| CA2423806C (en) | 2000-09-29 | 2009-12-22 | Molecular Probes, Inc. | Modified carbocyanine dyes and their conjugates |
| US6972326B2 (en) | 2001-12-03 | 2005-12-06 | Molecular Probes, Inc. | Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes |
| US7205384B2 (en) | 2003-08-05 | 2007-04-17 | Ortho-Mcneil Pharmaceutical Inc. | Process for preparing peptidyl heterocyclic ketone derivatives |
| EP2607431B1 (en) | 2003-12-05 | 2016-08-24 | Life Technologies Corporation | Cyanine dye compounds |
| AU2005334458B9 (en) | 2004-07-23 | 2012-06-07 | Smith, Judith | Furin inhibitors |
| CA2651762A1 (en) | 2006-05-23 | 2007-11-29 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
| WO2009103432A2 (en) | 2008-02-21 | 2009-08-27 | Sanofi-Aventis | Covalently binding imaging probes |
| CN101942410A (zh) * | 2010-06-13 | 2011-01-12 | 浙江大学 | 牙龈卟啉单胞菌促血凝功能结构域hgp44基因的克隆重组菌及构建方法 |
| US8642622B2 (en) | 2010-06-16 | 2014-02-04 | Bristol-Myers Squibb Company | Piperidinyl compound as a modulator of chemokine receptor activity |
| EA201590197A1 (ru) | 2012-08-23 | 2015-07-30 | Алиос Биофарма, Инк. | Соединения для лечения парамиксовирусных вирусных инфекций |
| EP4218829A3 (en) * | 2013-03-15 | 2023-08-16 | The Board of Trustees of the Leland Stanford Junior University | Activity-based probe compounds, compositions, and methods of use |
| CZ2014527A3 (cs) | 2014-08-05 | 2016-02-17 | Ústav Organické Chemie A Biochemie Akademie Věd Čr, V.V.I. | Způsob detekce aktivní formy analytů ve vzorku a stanovení schopnosti dalších látek vázat se do aktivních míst těchto analytů |
| PT3204352T (pt) * | 2014-10-06 | 2020-09-23 | Cortexyme Inc | Inibidores de lisina-gingipaína |
| ES2992410T3 (es) | 2016-09-16 | 2024-12-12 | Lighthouse Pharmaceuticals Inc | Inhibidores cetónicos de la lisina gingipaína |
| WO2018064119A1 (en) | 2016-09-28 | 2018-04-05 | Blade Therapeutics, Inc. | Calpain modulators and therapeutic uses thereof |
| AU2018222093B2 (en) | 2017-02-15 | 2022-03-31 | Genentech, Inc. | Macrocyclic broad spectrum antibiotics |
| CN110944637A (zh) | 2017-05-10 | 2020-03-31 | 库特克希米公司 | 氨基吡啶化合物及其制备方法和使用方法 |
-
2017
- 2017-09-15 ES ES17851664T patent/ES2992410T3/es active Active
- 2017-09-15 PE PE2019000533A patent/PE20190473A1/es unknown
- 2017-09-15 KR KR1020197010797A patent/KR102780603B1/ko active Active
- 2017-09-15 CN CN201780068518.0A patent/CN109983012B/zh active Active
- 2017-09-15 DK DK17851664.7T patent/DK3512846T3/da active
- 2017-09-15 WO PCT/US2017/051912 patent/WO2018053353A1/en not_active Ceased
- 2017-09-15 TW TW106131764A patent/TWI787202B/zh active
- 2017-09-15 CA CA3036862A patent/CA3036862A1/en active Pending
- 2017-09-15 RU RU2019111188A patent/RU2019111188A/ru unknown
- 2017-09-15 EP EP24187049.2A patent/EP4480541A3/en active Pending
- 2017-09-15 AU AU2017326466A patent/AU2017326466B2/en active Active
- 2017-09-15 EP EP17851664.7A patent/EP3512846B1/en active Active
- 2017-09-15 MX MX2019003087A patent/MX2019003087A/es unknown
- 2017-09-15 JP JP2019514780A patent/JP7113815B2/ja active Active
-
2019
- 2019-03-14 US US16/353,786 patent/US10730826B2/en active Active
- 2019-03-14 IL IL265389A patent/IL265389A/en unknown
- 2019-03-15 PH PH12019500570A patent/PH12019500570A1/en unknown
- 2019-03-15 CL CL2019000687A patent/CL2019000687A1/es unknown
- 2019-03-27 CO CONC2019/0002950A patent/CO2019002950A2/es unknown
-
2020
- 2020-06-11 US US16/899,376 patent/US11325884B2/en active Active
-
2022
- 2022-02-11 AU AU2022200927A patent/AU2022200927B2/en active Active
- 2022-05-09 US US17/740,260 patent/US12110263B2/en active Active
-
2024
- 2024-10-03 US US18/905,445 patent/US20250270162A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020519606A5 (https=) | ||
| JP2019534861A5 (https=) | ||
| EP3658538B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| JP2018534300A5 (https=) | ||
| JP2021529780A (ja) | Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法 | |
| JP2014520072A5 (https=) | ||
| JP2014513046A5 (https=) | ||
| JP2019501133A5 (https=) | ||
| JP2018502891A5 (https=) | ||
| JP2019533642A5 (https=) | ||
| KR940701383A (ko) | 질소 함유 헤테로사이클릭 화합물의 플루오로알콕시벤질아미노 유도체 | |
| JP2011515482A5 (https=) | ||
| JP2014503528A5 (https=) | ||
| JP2018515492A5 (https=) | ||
| JP2017531692A5 (https=) | ||
| JP2014515406A5 (https=) | ||
| AR072249A1 (es) | Inhibidores de amida hidrolasa de acido graso. usos. metodos. | |
| RU2009105179A (ru) | Сульфониламинокарбонилпроизводные амидов холевой кислоты для применения в качестве иммуномодуляторов | |
| JP2020533352A5 (https=) | ||
| JP2019510039A5 (https=) | ||
| JP2006509749A5 (https=) | ||
| JP2013542267A5 (https=) | ||
| JP2013510884A5 (https=) | ||
| JP2017505293A5 (https=) | ||
| JP2016516074A5 (https=) |